



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

July 03, 2019

National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex
Bandra (E)
Mumbai 400 051

Scrip Code : JBCHEPHARM

Dear Sir,

Sub: Successful US FDA inspection of new Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat

We wish to inform you that the US FDA has concluded inspection of Company's newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat. At the end of inspection, no objectionable observations were found and hence no Form 483 was issued. The said inspection was carried out from 24-6-2019 to 28-6-2019. This facility has capacity of 2 billion tablets per annum, which is expandable to 9 billion tablets per annum. This new facility has already been approved by EU authorities in February 2019 and classified as cGMP compliant.

The new facility will augment the Company's manufacturing capacity for regulated markets like USA and EU as and when the product approvals are received.

We request you to take the above announcement on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary & Vice President - Compliance